Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

NCT00848601 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma

Conditions

Interventions

Sponsor

Astex Pharmaceuticals, Inc.